---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028629"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:36:15.529275+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anebulo awarded up to $1.9M NIDA grant for IV selonabant development

## Summary
- Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.
- Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.
- Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.
- CEO notes grant validates progress and supports IV formulation clinical testing.

## SEC filing metadata
- accession: 0001493152-24-028629
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/0001493152-24-028629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028629
- JSON: https://secwatch.observer/filing/0001493152-24-028629.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.